EEF1A1P28: A Potential Drug Target and Biomarker in Eukaryotes

Target Name: EEF1A1P28

NCBI ID: G442709

EEF1A1P28

Other Name(s): eukaryotic translation elongation factor 1 alpha 1 pseudogene 28 | Eukaryotic translation elongation factor 1 alpha 1 pseudogene 28

EEF1A1P28: A Potential Drug Target and Biomarker in Eukaryotes

The eukaryotic translation elongation factor 1 alpha 1 pseudogene 28 (EEF1A1P28) is a non-coding RNA molecule that plays a critical role in the regulation of protein translation in eukaryotic cells. It is a key component of the eukaryotic translation machinery, which is responsible for the production of functional proteins from mRNAs. Mutations in the EEF1A1P28 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, targeting this gene has the potential to provide new therapeutic options for these diseases.

EEF1A1P28 functions as a negative regulator of the eukaryotic translation machinery. It interacts with the protein translation factor TOR, which is critical for the initiation of protein synthesis. TOR is a cytoplasmic protein that plays a central role in the regulation of cell growth, metabolism, and autophagy. It is composed of a nucleotide-protein complex and a associated protein, TOR-interactive protein (TIP), which functions as a scaffold to recruit the necessary components of the translation machinery to the cytoplasmic domain of TOR.

EEF1A1P28 is a key regulator of the TOR complex. It contains a conserved domain that is similar to the TOR-interactive protein (TIP) domain, which is critical for its interaction with TOR. The EEF1A1P28 protein contains a unique N-terminal region that is involved in the formation of a complex with TOR. This region contains a conserved motif that is similar to the TOR-interactive protein (TIP) domain, which is located in the N-terminus of TOR.

The EEF1A1P28 gene has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. EEF1A1P28 mutations have been linked to the development of various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, a missense mutation in the EEF1A1P28 gene has been linked to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its role in the regulation of the translation machinery, EEF1A1P28 has also been shown to play a critical role in the regulation of cell growth and metabolism. It has been shown to be involved in the regulation of cell proliferation, apoptosis, and autophagy. For example, studies have shown that EEF1A1P28 plays a role in the regulation of cell apoptosis, which is a critical mechanism for the elimination of damaged or dysfunctional cells.

EEF1A1P28 has also been shown to play a critical role in the regulation of protein translation. It has been shown to interact with various translation factors, including the eukaryotic translation initiation factor (eIF4F), which is responsible for the initiation of protein synthesis. The interaction between EEF1A1P28 and eIF4F suggests that EEF1A1P28 may be a potential drug target for the treatment of eukaryotic translation-related diseases.

In conclusion, EEF1A1P28 is a non-coding RNA molecule that plays a critical role in the regulation of the eukaryotic translation machinery. Its unique N-terminal region, which contains a conserved motif similar to the TOR-interactive protein (TIP) domain, makes it a potential drug target for the treatment of various eukaryotic translation-related diseases. Further research is needed to understand the full role of EEF1A1P28 in the regulation of the eukaryotic translation machinery and its potential as a drug target.

Protein Name: Eukaryotic Translation Elongation Factor 1 Alpha 1 Pseudogene 28

The "EEF1A1P28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1A1P28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets